CoChat

EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients

Open access
Bae, Nack Cheon, Chae, Myung Hwa, Lee, Myung Hoon, Kim, Kyung Mee, Lee, Eung Bae, Kim, Chang Ho, Park, Tae-In, Han, Sung Beom, Jheon, Sanghoon, Jung, Tae Hoon, Park, Jae Yong · 2007 · Cancer Genetics and Cytogenetics
Cited by 82

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

The epidermal growth factor receptor (EGFR), and its family members play an important role in the development and progression of lung cancers. It has been reported that somatic mutations in the tyrosine kinase domain of the EGFR or ERBB2 genes occur in a subset of patients with lung cancer. We searched for mutations of the EGFR, ERBB2, and KRAS genes in surgically resected non-small cell lung cancers (NSCLCs) to determine the prevalence of these mutations in Korean lung cancer patients. In addition, we examined the relationship between the mutations and clinicopathologic features of lung cancers. Mutations of the EGFR, ERBB2, and KRAS genes were determined by polymerase chain reaction-based direct sequencing in 115 surgically resected non-small cell lung cancers. EGFR mutations were present in 20 patients (17.4%). The EGFR mutations were found only in adenocarcinomas (20 of 55 adenocarcinomas, 36.4%). The ERBB2 mutation was found in 1 adenocarcinoma of the 115 NSCLCs (0.9% overall; 1.8% of the 55 adenocarcinomas). KRAS mutations were found in 6 (5.2%) of the 115 NSCLCs (2 of 60 squamous cell carcinomas, or 3.3%, and 4 of 55 adenocarcinomas, or 7.3%). EGFR mutations in adenocarcinomas were more frequent in women (P = 0.02) and in never-smokers (P = 0.004). EGFR mutations in adenocarcinomas were not associated with pathologic stage in never-smokers, but were more frequent in pathologic stage II-IV than in stage I in ever-smokers (P = 0.01). Of the 55 adenocarcinomas, 25 (45.5%) had mutations of one or another of the three genes; EGFR mutations were never found in adenocarcinomas together with ERBB2 or KRAS mutations. These findings suggest that the EGFR mutation is frequent in Korean lung cancer patients, and that the ERBB2 mutation is rare. Further studies are needed to investigate the role of EGFR mutations in the carcinogenesis of adenocarcinoma among smokers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cancergencyto.2006.10.007

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 82

Metadata

Authors
Bae, N. C., Chae, M. H., Lee, M. H., Kim, K. M., Lee, E. B., Kim, C. H., Park, T.-I., Han, S. B., Jheon, S., Jung, T. H., & Park, J. Y.
Venue
Cancer Genetics and Cytogenetics
Publisher
Elsevier BV
Published
2007-03
Volume
173
Issue
2
Pages
107-113
ISSN
0165-4608 (ISSN-L)
OpenAlex
W1972380802
Cited by
82
References
2
FWCI
4.43
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. https://app.cochat.ai/papers/10.1016/j.cancergencyto.2006.10.007
The paper
Bae, N. C., Chae, M. H., Lee, M. H., Kim, K. M., Lee, E. B., Kim, C. H., Park, T.-I., Han, S. B., Jheon, S., Jung, T. H., & Park, J. Y. (2007). EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genetics and Cytogenetics. https://doi.org/10.1016/j.cancergencyto.2006.10.007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.